Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | G6PD | P11413 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15609444 | 0.80 | ACHE (0.32) | HPGDCA2LPLLIPG | |
| SCHEMBL30154900 | 0.77 | CA3 (0.36) | KDM4E | |
| SCHEMBL18128452 | 0.77 | CA3 (0.36) | KDM4E | |
| SCHEMBL3318129 | 0.77 | HTR2A (0.36) | CYP3A4 | |
| SCHEMBL29957677 | 0.77 | HTR2A (0.36) | CYP3A4 | |
| SCHEMBL29661842 | 0.74 | CYP3A4 (0.39) | TDP1TSHRHPGDALDH1A1CYP1A2 | |
| SCHEMBL22866473 | 0.74 | CYP3A4 (0.39) | TDP1TSHRHPGDALDH1A1CYP1A2 | |
| SCHEMBL1679453 | 0.74 | TP53 (0.40) | TP53TDP1TSHRCASP1PDE10A | |
| SCHEMBL29956362 | 0.74 | ENPP2 (0.39) | KMT2AKDM4EMAPTPKMMAPK1 | |
| SCHEMBL15476241 | 0.74 | ENPP2 (0.39) | KMT2AKDM4EMAPTPKMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970274-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| EP-2888266-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-01-11 | — | — | EP | disclosed |
| EP-2888266-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-01-11 | — | — | EP | disclosed |
| US-9527842-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| US-20160024077-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| EP-2970274-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2888266-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2015-07-01 | — | — | EP | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| WO-2014159959-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| WO-2014028384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014028384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | TP53 1137/4885TDP1 1232/4885TSHR 4185/4885 |
| US-20160024077-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, RTF2, MAVS | TP53 1514/4885TDP1 422/4885TSHR 4838/4885 |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | TP53 1355/4885TDP1 194/4885TSHR 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.